Influences of histamine H1 receptor antagonists on maximal electroshock seizure in infant rats

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 3, 2007, Pages 477-480

  Ishikawa, Takashi ^a   Takechi, Kenshi ^a   Rahman, Md Ashequr ^a   Ago, Jun ^a   Matsumoto, Naotaka ^a   Murakami, Aya ^a   Kamei, Chiaki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Electroencephalogram seizure; Epinastine; Fexofenadine; Infant rat; Maximal electroshock; Tonic extensor seizure

Indexed keywords

CHLORPHENIRAMINE; CYPROHEPTADINE; DIPHENHYDRAMINE; EPINASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOTIFEN; KETOTIFEN FUMARATE; DIBENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; TERFENADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; CONVULSION; ELECTRIC SHOCK; ELECTROENCEPHALOGRAM; EPILEPTOGENESIS; MALE; NONHUMAN; RAT; ANIMAL; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SEIZURE; SUCKLING; TIME; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, SUCKLING; CHLORPHENIRAMINE; CYPROHEPTADINE; DIBENZAZEPINES; DIPHENHYDRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ELECTROSHOCK; HISTAMINE H1 ANTAGONISTS; IMIDAZOLES; KETOTIFEN; MALE; RATS; RATS, WISTAR; SEIZURES; TERFENADINE; TIME FACTORS;

EID: 33847665191     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.477     Document Type: Article

References (22)

1. Casale T. B., Blaiss M. S., Gelfand E., Gilmore T., Harvey P. D., Hindmarch I., Simons F. E., Spangler D. L., Szefler S. J., Terndrup T. E., Waldman S. A., Weiler J., Wong D. F., J. Allergy Clin. Immunol., 111, S835-S842 (2003).
2. Herman S. M., Vender R. B., J. Cutan. Med. Surg., 7, 467-473 (2003).
3. Bender B. G., Berning S., Dudden R., Milgrom H., Tran Z. V., J. Allergy Clin. Immunol., 111, 770-776 (2003).
4. Nicholson A. N., Pascoe P. A., Turner C., Ganellin C. R., Greengrass P. M., Casy A. F., Mercer A. D., Br. J. Pharmacol., 104, 270-276 (1991).
5. Wyngaarden J. B., Seevers M. H., J. Am. Med. Assoc., 145, 277-282 (1951).
6. Kamei C., Ohuchi M., Sugimoto Y., Okuma C., Brain Res., 887, 183-186 (2000).
7. Yokoyama H., Iinuma K., Yanai K., Watanabe T., Sakurai E., Onodera K., Meth. Find. Exp. Clin. Pharmacol., 15, 183-188 (1993).
8. Yanai K., Ryu J. H., Watanabe T., Iwata R., Ido T., Asakura M., Matsumura R., Itoh M., Meth. Find. Exp. Clin. Pharmacol., 17, 64-69 (1995).
9. Tashiro M., Mochizuki H., Iwabuchi K., Sakurada Y., Itoh M., Watanabe T., Yanai K., Life Sci., 72, 409-414 (2002).
10. Davenport V. D., Davenport H. W., J. Nutr., 36, 139-151 (1948).
11. Holmes G. L., Thompson J. L., Brain Res., 467, 51-59 (1988).
12. Himwich W. A., "Development and Aging in the Nervous System," ed. by Rockstein M., Academic Press, New York, 1973, pp. 151-169.
13. Paxinos G., Watson C., "The Rat Brain in Stereotaxic Coordinates," 2nd ed., Academic Press, San Diego, 1986.
14. Woodbury L. A., Davenport V. D., Arch. Int. Pharmacodyn., 92, 97-107 (1952).
15. Goodman L. S., Grewal M. S., Brown W. C., Swinyard E. A., J. Pharmacol. Exp. Ther., 108, 168-176 (1953).
16. Goldstein L., Murphree H. B., Pfeiffer C. C., J. Clin. Pharmacol. J. New Drugs, 8, 42-52 (1968).
17. Kamei C., Ishizawa K., Kakinoki H., Fukunaga M., Epilepsy Res., 30, 187-194 (1998).
18. Tuomisto L., Tacke U., Neuropharmacology, 25, 955-958 (1986).
19. Kubo N., Shirakawa O., Kuno T., Tanaka C., Jpn. J. Pharmacol., 43, 277-282 (1987).
20. Tasaka K., Kamei C., Nakano S., Tsujimoto S., Chung Y. H., Oyo Yakuri/Pharmacometrics, 38, 53-62 (1989).
21. Yokoyama H., Sato M., Iinuma K., Onodera K., Watanabe T., Neurosci. Lett., 217, 194-196 (1996).
22. Toman J. E. P., Swinyard E. A., Goodman L. S., Neurophysiology, 9, 231-250 (1946).